Clinical Trial Update: Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1b/2 clinical trial is evaluating low-dose radiotherapy in combination with AK104 and chemotherapy as first-line treatment for extensive-stage small cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)

Snippet

Sponsor: Sichuan University | Conditions: SCLC, Extensive Stage | Phase 1, Phase 2 | Status: RECRUITING